Seeking a place among giants in the oncolytic virus field, little Cold Genesys bags $22M Series C
A small biotech out of California has refueled with $22 million for the next leg of its quest in oncolytic immunotherapies, a hot field …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
